eHealth, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. Comparisons below are primarily with fiscal 2022.
Business context
eHealth operates an online and telephone health-insurance marketplace, earning most revenue from carrier commissions. Its Medicare segment generated about 90% of 2023 revenue; the remainder came principally from Employer and Individual (E&I), renamed from Individual, Family and Small Business in the fourth quarter. Consumers use its services without charge, and eHealth does not underwrite insurance risk.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Total revenue | $452.9 million | $405.4 million | Up 12% |
| Commission revenue | $403.9 million | $361.2 million | Up 12% |
| Other revenue | $48.9 million | $44.1 million | Up 11% |
| Operating loss | $29.1 million | $102.7 million | Narrowed |
| Net loss | $28.2 million | $88.7 million | Narrowed |
| Loss attributable to common stockholders | $66.5 million | $119.4 million | Narrowed |
| Basic and diluted loss per share | $2.37 | $4.36 | Improved |
| Cash used in operating activities | $6.7 million | $26.9 million | Outflow decreased |
- Operating margin improved to approximately negative 6% from negative 25%. Marketing and advertising expense fell 11% to $173.3 million, while customer care and enrollment expense rose 13% to $159.1 million. Technology and content expense declined 23% to $61.0 million; general and administrative expense increased 21% to $86.8 million.
- Net income remained negative despite the improvement. Results included $9.5 million of other income, primarily reflecting higher interest income, and a $2.4 million income tax benefit.
- Medicare revenue rose 12% to $406.5 million. Medicare segment profit was $54.7 million, versus a $9.9 million segment loss in 2022. E&I revenue increased 6% to $46.4 million and segment profit rose 21% to $25.8 million. Segment profit excludes certain corporate costs and other items; it is not consolidated operating income.
- Cash, cash equivalents and short-term marketable securities totaled $121.7 million at year-end, down from $144.4 million. Net cash used in investing activities was $15.9 million and net cash used in financing activities was $6.2 million.
- Term-loan carrying value was $67.8 million, with a 13.15% interest rate at year-end and maturity in February 2025. The company said it was in compliance with loan covenants. It expects current liquidity and collections to fund operations for at least 12 months after filing and to refinance the loan or pursue alternatives.
- Net commissions receivable was $918.2 million, including $673.5 million non-current. This material asset depends on estimates of member retention, plan duration and future commission collections.
Changes versus 2022 and unusual items
- Total approved members declined 10% to 429,196; estimated membership declined 6% to 1.26 million. However, Medicare Advantage approved members grew 22% in the fourth-quarter 2023 annual enrollment period compared with the same period in 2022.
- Commission revenue included $48.1 million of positive net adjustment revenue from prior-period enrollments, compared with $6.4 million in 2022. This comprised $33.5 million in Medicare and $14.5 million in E&I, reflecting management’s revised estimates, including stronger retention and commission trends. These adjustments are judgmental and may reverse or change.
- Estimated constrained lifetime commission value per approved member increased for Medicare Advantage to $1,049 from $975 and Medicare Part D to $220 from $194; Medicare Supplement declined to $891 from $935. Values also increased for the listed individual, family, vision and small-business products.
- No impairment, restructuring or other charges were recorded in 2023, versus $19.6 million in 2022, including office-related impairment and restructuring costs. The company reported $23.2 million of stock-based compensation expense in 2023.
- Operating cash outflow improved, but increased commissions receivable used $33.6 million of operating cash. Commission expenses are generally incurred before related cash collections are received over time.
Outlook, risks and contingencies
- Management plans to pursue further enrollment growth in 2024 while continuing to emphasize enrollment quality, member retention, customer experience, targeted marketing and platform improvements. It also intends to develop E&I and other revenue sources, including employer offerings and ICHRA opportunities. The filing provides no specific 2024 financial guidance.
- Key operating risks include intense competition, dependence on a small number of carriers and marketing channels, seasonal enrollment patterns, agent hiring and productivity, and uncertainty in retention and commission estimates. Humana, UnitedHealthcare and Aetna represented 27%, 23% and 15% of 2023 revenue, respectively.
- Regulatory exposure is significant. CMS finalized additional Medicare marketing and enrollment requirements in 2023 and proposed 2025 rules that could change broker compensation and administrative payments. The company cautions these proposals could adversely affect its business if adopted. New FCC consent rules are expected to take effect around March 2025.
- In December 2023, CMS sent proposed broker-compensation rules; the filing describes them as proposals, not enacted requirements. A Senate Finance Committee letter in January 2024 requested information about lead generation, marketing and Medicare Advantage enrollment. The company also disclosed a 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts regarding carrier arrangements.
- The securities class action was dismissed with prejudice in October 2023, with judgment for the company in November. The federal derivative action was voluntarily dismissed in January 2024; another derivative matter remained stayed as described in the filing. No material litigation accruals were recorded at year-end.
- The company failed its preferred-stock investor’s 2.5x minimum asset coverage ratio at the September 30, 2023 measurement date, although it met the minimum liquidity requirement at December 31, 2023. The failure gave H.I.G. specified additional governance and approval rights. Management said the failure does not accelerate preferred-stock redemption and was not expected to materially impair near-term funding capacity.
- Series A preferred stock carries an 8% annual dividend, including a 2% cash portion after April 2023, and senior rights. Its recorded value was $298.1 million at year-end; redemption rights begin in April 2027. The preferred stock was convertible into 3.4 million common shares as of year-end, creating potential dilution and competing claims on capital.
- Management began self-insuring a substantial portion of U.S. employee health benefits in 2023; the year-end liability was $2.5 million. The filing identifies risks from claims exceeding estimates or coverage limits.
- The company reported no cybersecurity incidents determined to be material as of the filing date. It identified cybersecurity, privacy compliance, China operations and third-party system availability as continuing risks. The financial statements received an unqualified audit opinion; management and the auditor found internal control over financial reporting effective.
Important facts for investors to verify
- How much of 2023 revenue growth and improved losses depended on the $48.1 million of prior-period commission adjustments, and whether those estimates are supported by subsequent cash collections.
- Current status and terms of the H.I.G. asset-coverage and liquidity requirements, associated governance rights, preferred-stock accretion and future cash dividend obligations.
- Refinancing plans and available funding for the $67.8 million secured term loan due in February 2025, given its 13.15% year-end rate and lender covenants.
- Whether 2023’s fourth-quarter Medicare Advantage enrollment growth can be sustained while overall approved members and year-end estimated membership have declined.
- Potential effects of CMS broker-compensation proposals and other marketing rules on commissions, carrier relationships, customer acquisition and enrollment processes.
- Carrier concentration, member retention, and the accuracy and collectability of the $918.2 million commissions-receivable balance; carrier cancellation information may be delayed or incomplete.